Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Down 21.9% in January

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totaling 105,482 shares, a decline of 21.9% from the December 31st total of 135,073 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average trading volume of 47,847 shares, the short-interest ratio is presently 2.2 days. Based on an average trading volume of 47,847 shares, the short-interest ratio is presently 2.2 days. Currently, 2.2% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on EVAX. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Evaxion A/S in a report on Monday, October 20th. Edward Jones initiated coverage on shares of Evaxion A/S in a research report on Thursday, October 30th. They set a “buy” rating and a $10.00 price target on the stock. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Finally, Lake Street Capital increased their price target on Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion A/S stock. Wesbanco Bank Inc. purchased a new stake in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $48,000. Wesbanco Bank Inc. owned 0.12% of Evaxion A/S at the end of the most recent quarter. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Stock Up 2.9%

Shares of EVAX stock traded up $0.09 on Tuesday, reaching $3.19. The stock had a trading volume of 84,585 shares, compared to its average volume of 69,732. Evaxion A/S has a 12 month low of $1.20 and a 12 month high of $12.15. The firm’s 50-day moving average is $5.01 and its two-hundred day moving average is $4.55.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.